I am a neuroscientist with expertise in abuse liability and pharmacology, focused on developing novel therapeutics and harm reduction tools for addiction, depression, and anxiety. I have wide-ranging research experience across academia and industry that spans from molecular to behavioral, and from preclinical to clinical. My most recent experience at the FDA regulated and studied addictive drugs. Collectively, this diverse background has provided me with unique and comprehensive insights across the entire therapeutics development pipeline, from initial target identification to clinical evaluation and eventual regulatory submission.